Rituximab Maintenance Boosts Survival for Older Adults With MRD-Negative MCL

(MedPage Today) -- Maintenance therapy with rituximab yielded better survival outcomes for older patients with minimal residual disease (MRD) negativity after induction therapy for mantle cell lymphoma (MCL), results from the European Mantle Cell...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news